NCT03028441View on ClinicalTrials.gov

Phase I Trial of Measles Vectored Chikungungya Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

January 17, 2019

Study Completion Date

January 17, 2019

Conditions
Chikungunya Virus Infection
Interventions
OTHER

Placebo

Placebo

BIOLOGICAL

VRC-CHKVLP059-00-VP

Measles-vectored Chikungunya vaccine

Trial Locations (3)

30322-1014

Emory Children's Center - Pediatric Infectious Diseases, Atlanta

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03028441 - Phase I Trial of Measles Vectored Chikungungya Vaccine | Biotech Hunter | Biotech Hunter